
INS018_055 Phase IIa Results: First AI-Designed Drug
Analyze the Phase IIa clinical trial results of INS018_055 (rentosertib), the first AI-designed drug by Insilico Medicine targeting TNIK for IPF treatment.

Analyze the Phase IIa clinical trial results of INS018_055 (rentosertib), the first AI-designed drug by Insilico Medicine targeting TNIK for IPF treatment.
© 2026 IntuitionLabs. All rights reserved.